Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2022 Q2- Text added to 2022 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Bad
|
New words:
activin, American, ASCO, background, bear, Belgium, cancelled, carcinogenic, carcinogenicity, Carolina, chairman, chemical, circular, Clalit, cohort, Colombia, Conrad, constituted, creation, detected, dispute, domain, doravirine, engineered, epithelial, facie, fallopian, faster, fc, found, Frazier, Genitourinary, Greece, group, incidence, ingredient, injunction, injury, Israel, Kenneth, led, main, media, MHLW, mice, Moderna, multicomponent, natriuretic, NEJM, nemtabrutinib, newer, nitrosamine, NTTP, orna, orthostatic, Oxford, Pacific, PANORAMIC, people, peptide, peritoneal, Phosphodiesterase, pioneering, prednisolone, prednisone, PrEP, presence, President, prima, proportion, protocol, purported, redesign, refused, reissued, restraining, retire, RNA, Robert, schizophrenia, score, secondary, shift, shorter, showed, stable, STELLAR, stipulated, stored, succeed, suffered, suppressed, switch, Symposium, syndrome, tachycardia, temporary, trace, transgenic, tube, untreated, upholding, walk, water, Western, worsening, younger
Valuein 2022 Q2 filing- Value in 2022 Q3 filing
Original filings
Filing view